Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

Launched by DOGWOOD THERAPEUTICS INC. · Feb 21, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the safety and effectiveness of a treatment called Halneuron for patients experiencing nerve pain caused by chemotherapy. Specifically, it focuses on individuals who have developed neuropathic pain from certain types of chemotherapy drugs, known as platinum and taxane. The trial is currently recruiting participants who are 18 years or older and have had this type of pain after receiving chemotherapy, but who do not have any active cancer.

Eligible participants will receive a single injection of Halneuron and will be monitored for its effects on their pain. If you’re considering joining this trial, it’s important to know that you should not have other causes for your nerve pain or have received Halneuron before. This study aims to help improve the quality of life for those suffering from pain related to cancer treatment, and your participation could contribute valuable information to this important area of research.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female patients aged ≥18 years.
• • Neuropathic pain has been present and is attributed to platinum and/or taxane chemotherapy.
• • Patient has received a cancer chemotherapy regimen that included taxanes and/or platinum and has no active or discernible disease progression.
• Exclusion Criteria:
• • Current neuropathic pain with symptoms similar to CINP but attributed to causes other than platinum or taxane chemotherapy.
• • Patients who have received HAL at any time prior to screening.